Join Heidelberg Pharma for a virtual key opinion leader (KOL) event featuring Robert Z. Orlowski, MD, PhD (MD Anderson Cancer Center) and Shambavi Richard, MD (Mount Sinai), who will discuss the current unmet need and treatment landscape in relapsed or refractory multiple myeloma.

The event will focus on recent clinical data from the Phase I/IIa, trial of HDP-101, an anti-B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC) with a novel amanitin payload. The results were presented at the 21^st International Myeloma Society (IMS) Annual Meeting, which took place from September 25 – 28, 2024 in Rio de Janeiro, Brazil.

A live question and answer session will follow the formal presentation.